Filing Details

Accession Number:
0001209191-22-005426
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-01-28 16:39:37
Reporting Period:
2022-01-26
Accepted Time:
2022-01-28 16:39:37
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1290149 Sierra Oncology Inc. SRRA Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1819688 D. William Turner C/O Sierra Oncology, Inc.
1820 Gateway Drive, Suite 110
San Mateo CA 94404
Chief Reg & Tech Ops Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-01-26 5,000 $12.05 5,000 No 4 M Direct
Common Stock Disposition 2022-01-26 5,000 $27.05 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Acquisiton 2022-01-26 5,000 $0.00 5,000 $12.05
Common Stock Stock Option (Right to Buy) Acquisiton 2022-01-28 12,250 $0.00 12,250 $12.15
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2030-08-04 No 4 M Direct
12,250 2022-01-28 2030-08-12 No 4 A Direct
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 23, 2022. The Reporting Person is subject to a Lock-Up Letter Agreement that expires on April 26, 2022. The sale of shares is a permissible exemption under the terms of the Lock-Up Letter Agreement.
  2. On August 4, 2021, the option vested as to 25% of the total shares granted on August 4, 2020, with the remaining shares from that grant vesting in equal monthly installments over the following 36 months, with 100% of the total shares vested on August 4, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
  3. On August 12, 2020, the Reporting Person was granted an option to purchase 49,000 shares of common stock. The option vests based on the satisfaction by Issuer of certain performance criteria. The achievement of one of the performance criteria resulted in vesting of the option as to 12,250 shares.